Sign In
Buy NVCT
$18.44
+0.0900 (+0.490%)
At Close: Jul 13, 2026
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
07:30pm, Monday, 25'th Sep 2023
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
08:00am, Thursday, 21'st Sep 2023
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative
Nuvectis: Early Stage Company That's Low On Cash
08:03am, Wednesday, 06'th Sep 2023
Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ovarian cancer. Preclinical trials have shown strong antitumor activity of NXP800, inclu
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
08:00am, Wednesday, 06'th Sep 2023
Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET
